Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)

•Ovarian cancer recurrences can be detected by CA-125 increase before apparition of radiological or clinical manifestations.•There is an unmet medical need for asymptomatic patients with CA-125 increase.•Regorafenib has modest efficacy and poor tolerance in recurrent ovarian cancer patients.•Maintenance treatment or surveillance remain the standard of care in this situation.